Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Abgenix, CuraGen in cancer, autoimmune drug deal

Executive Summary

In a five-year deal, Abgenix and CuraGen will co-develop drugs to treat a variety of diseases including autoimmune and cancer. Abgenix buys (uf)$15mm of CuraGen common stock up front, and CuraGen provides research funding of up to $1.5mm each year.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Co-Promotion
    • Includes Contract
    • Product or Technology Swap
    • R+D and Marketing-Licensing

Related Companies